A carregar...
Rationale and design of LUX-Head & Neck 1: a randomised, Phase III trial of afatinib versus methotrexate in patients with recurrent and/or metastatic head and neck squamous cell carcinoma who progressed after platinum-based therapy
BACKGROUND: Patients with recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) receiving platinum-based chemotherapy as their first-line treatment have a dismal prognosis, with a median overall survival (OS) of ~7 months. Methotrexate is sometimes used following platinum f...
Na minha lista:
Main Authors: | , , , , |
---|---|
Formato: | Artigo |
Idioma: | Inglês |
Publicado em: |
BioMed Central
2014
|
Assuntos: | |
Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4079914/ https://ncbi.nlm.nih.gov/pubmed/24973959 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1471-2407-14-473 |
Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|